John Mohr
Chief Tech/Sci/R&D Officer at SCPHARMACEUTICALS INC.
John Mohr active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SCPHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 2018-04-30 | - |
Career history of John Mohr
Former positions of John Mohr
| Companies | Position | Start | End |
|---|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2015-06-30 | 2016-04-30 |
| THE MEDICINES COMPANY | Chief Tech/Sci/R&D Officer | 2015-02-28 | 2015-05-31 |
| The University of Texas Medical School At Houston | Corporate Officer/Principal | 2002-12-31 | 2007-09-30 |
Training of John Mohr
| Texas A&M University | Undergraduate Degree |
| University of Houston | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SCPHARMACEUTICALS INC. | Health Technology |
| Private companies | 2 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- John Mohr
- Experience